{"id":37554,"date":"2026-08-10T11:57:09","date_gmt":"2026-08-10T11:57:09","guid":{"rendered":"https:\/\/itbusinesstoday.com\/?p=37554"},"modified":"2026-08-10T11:57:09","modified_gmt":"2026-08-10T11:57:09","slug":"innate-pharma-partners-with-sobi-on-lacutamab","status":"publish","type":"post","link":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/","title":{"rendered":"\u30a4\u30cd\u30a4\u30c8\u30fb\u30d5\u30a1\u30fc\u30de\u3001\u30e9\u30af\u30bf\u30de\u30d6\u306b\u95a2\u3057\u3066\u30bd\u30d3\u3068\u63d0\u643a"},"content":{"rendered":"<?xml encoding=\"utf-8\" ?><p><a href=\"https:\/\/www.innate-pharma.com\/\" data-no-translation=\"\">Innate Pharma<\/a> SA&nbsp; and Swedish Orphan Biovitrum AB (publ) (<a href=\"https:\/\/www.sobi.com\/en\" data-no-translation=\"\">Sobi<\/a>) today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T-cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in S&eacute;zary syndrome, a subtype of CTCL.<\/p><p>Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing in S&eacute;zary syndrome. The planned TELLOMAK-3 study will subsequently support applications for full approvals in key jurisdictions in S&eacute;zary syndrome and mycosis fungoides, the most common subtype. Sobi will receive exclusive global rights to commercialize lacutamab upon potential accelerated approval and will be eligible to assume full global development rights following positive Phase 3 results. Closing of the transaction is subject to closing conditions, including the receipt of transaction related anti-trust clearance.<\/p><h3>\u30e9\u30af\u30bf\u30de\u30d6\u306b\u3064\u3044\u3066<\/h3><p>Lacutamab is a first-in-class anti-KIR3DL2 antibody, currently developed in cutaneous T-cell lymphoma (CTCL). CTCL is a group of rare non-Hodgkin lymphomas that includes S&eacute;zary syndrome, a rare and aggressive leukemic form, and mycosis fungoides, the most common subtype in CTCL.<\/p><h4>\u3053\u3061\u3089\u3082\u304a\u8aad\u307f\u304f\u3060\u3055\u3044\uff1a <a class=\"p-url\" href=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/em-systems-and-good-cycle-systems-merge-systems\/\" rel=\"bookmark\">EM Systems\u793e\u3068Good Cycle Systems\u793e\u304c\u5408\u4f75\u3057\u307e\u3057\u305f<\/a><\/h4><p>The program has received Fast Track designation from the FDA, PRIME designation from the EMA for S&eacute;zary syndrome, Orphan Drug designation in both the U.S. and EU for CTCL, and Breakthrough Therapy Designation from the FDA for relapsed or refractory S&eacute;zary syndrome. The program is advancing toward a pivotal Phase 3 TELLOMAK-3 study, an open-label, multicenter, randomized trial in patients with S&eacute;zary syndrome and mycosis fungoides who have failed at least one prior systemic therapy. The study includes a confirmatory cohort in S&eacute;zary syndrome intended to support a potential accelerated approval and upon study completion a full approval for S&eacute;zary syndrome, and a registrational cohort in mycosis fungoides intended to support full approval, with progression-free survival (PFS) as the primary endpoint.<\/p><p><strong>\u51fa\u5178\uff1a <a href=\"https:\/\/www.businesswire.com\/\" target=\"_blank\" rel=\"noopener\" data-no-translation=\"\">BUSINESS WIRE<\/a><\/strong><\/p>","protected":false},"excerpt":{"rendered":"<p>Innate Pharma SA&nbsp; and Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T-cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in S&eacute;zary syndrome, a subtype of CTCL.Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing in S&eacute;zary syndrome. The planned TELLOMAK-3 study will subsequently support applications for full approvals in key jurisdictions in S&eacute;zary syndrome and mycosis fungoides, the most common subtype. Sobi will receive exclusive global rights to commercialize lacutamab upon potential [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":37592,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"wprm-recipe-roundup-name":"","wprm-recipe-roundup-description":"","postBodyCss":"","postBodyMargin":[],"postBodyPadding":[],"postBodyBackground":{"backgroundType":"classic","gradient":""},"footnotes":""},"categories":[89,207,237,182],"tags":[14505,14509,14507,14506,14508],"ppma_author":[205],"class_list":["post-37554","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health-tech","category-international","category-news","category-pharma","tag-fda","tag-innate-pharma","tag-lacutamab","tag-sezary-syndrome","tag-sobi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Innate Pharma Licenses Lacutamab to Sobi<\/title>\n<meta name=\"description\" content=\"Innate Pharma enters a strategic partnership with Sobi to license Lacutamab for the treatment of T-cell lymphoma.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innate Pharma Licenses Lacutamab to Sobi\" \/>\n<meta property=\"og:description\" content=\"Innate Pharma enters a strategic partnership with Sobi to license Lacutamab for the treatment of T-cell lymphoma.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/\" \/>\n<meta property=\"og:site_name\" content=\"itbusinesstoday\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-10T11:57:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/08\/Innate-Pharma-Enters-Strategic-Partnership-With-Sobi-to-License-Lacutamab-in-T-cell-Lymphoma.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NewsDesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"NewsDesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u5206\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u30a4\u30cd\u30a4\u30c8\u30fb\u30d5\u30a1\u30fc\u30de\u3001\u30bd\u30d3\u793e\u306b\u30e9\u30af\u30bf\u30de\u30d6\u306e\u30e9\u30a4\u30bb\u30f3\u30b9\u4f9b\u4e0e","description":"\u30a4\u30cd\u30a4\u30c8\u30fb\u30d5\u30a1\u30fc\u30de\u306f\u3001T\u7d30\u80de\u30ea\u30f3\u30d1\u816b\u306e\u6cbb\u7642\u85ac\u300c\u30e9\u30af\u30bf\u30de\u30d6\u300d\u306e\u30e9\u30a4\u30bb\u30f3\u30b9\u4f9b\u4e0e\u3092\u3081\u3050\u308a\u3001\u30bd\u30d3\u793e\u3068\u6226\u7565\u7684\u63d0\u643a\u3092\u7de0\u7d50\u3057\u307e\u3057\u305f\u3002.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/","og_locale":"ja_JP","og_type":"article","og_title":"Innate Pharma Licenses Lacutamab to Sobi","og_description":"Innate Pharma enters a strategic partnership with Sobi to license Lacutamab for the treatment of T-cell lymphoma.","og_url":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/","og_site_name":"itbusinesstoday","article_published_time":"2026-08-10T11:57:09+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/08\/Innate-Pharma-Enters-Strategic-Partnership-With-Sobi-to-License-Lacutamab-in-T-cell-Lymphoma.webp","type":"image\/webp"}],"author":"NewsDesk","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"NewsDesk","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"2\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/#article","isPartOf":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/"},"author":{"name":"NewsDesk","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/d58d81f55e8acd257ab63d49fb4ea812"},"headline":"Innate Pharma Partners With Sobi on Lacutamab","datePublished":"2026-08-10T11:57:09+00:00","mainEntityOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/"},"wordCount":335,"publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/08\/Innate-Pharma-Enters-Strategic-Partnership-With-Sobi-to-License-Lacutamab-in-T-cell-Lymphoma.webp","keywords":["FDA","Innate Pharma","Lacutamab","S\u00e9zary syndrome","Sobi"],"articleSection":["Health Tech","International","News","Pharma"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/","url":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/","name":"\u30a4\u30cd\u30a4\u30c8\u30fb\u30d5\u30a1\u30fc\u30de\u3001\u30bd\u30d3\u793e\u306b\u30e9\u30af\u30bf\u30de\u30d6\u306e\u30e9\u30a4\u30bb\u30f3\u30b9\u4f9b\u4e0e","isPartOf":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website"},"primaryImageOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/#primaryimage"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/08\/Innate-Pharma-Enters-Strategic-Partnership-With-Sobi-to-License-Lacutamab-in-T-cell-Lymphoma.webp","datePublished":"2026-08-10T11:57:09+00:00","description":"\u30a4\u30cd\u30a4\u30c8\u30fb\u30d5\u30a1\u30fc\u30de\u306f\u3001T\u7d30\u80de\u30ea\u30f3\u30d1\u816b\u306e\u6cbb\u7642\u85ac\u300c\u30e9\u30af\u30bf\u30de\u30d6\u300d\u306e\u30e9\u30a4\u30bb\u30f3\u30b9\u4f9b\u4e0e\u3092\u3081\u3050\u308a\u3001\u30bd\u30d3\u793e\u3068\u6226\u7565\u7684\u63d0\u643a\u3092\u7de0\u7d50\u3057\u307e\u3057\u305f\u3002.","breadcrumb":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/itbusinesstoday.com\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/#primaryimage","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/08\/Innate-Pharma-Enters-Strategic-Partnership-With-Sobi-to-License-Lacutamab-in-T-cell-Lymphoma.webp","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/08\/Innate-Pharma-Enters-Strategic-Partnership-With-Sobi-to-License-Lacutamab-in-T-cell-Lymphoma.webp","width":1200,"height":800,"caption":"Innate Pharma"},{"@type":"BreadcrumbList","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/itbusinesstoday.com\/"},{"@type":"ListItem","position":2,"name":"Innate Pharma Partners With Sobi on Lacutamab"}]},{"@type":"WebSite","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","description":"","publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","width":663,"height":275,"caption":"itbusinesstoday"},"image":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/d58d81f55e8acd257ab63d49fb4ea812","name":"\u30cb\u30e5\u30fc\u30b9\u30c7\u30b9\u30af","image":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png74f313ad3d6fa27a1eee85c30be63d03","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","caption":"NewsDesk"},"sameAs":["https:\/\/itbusinesstoday.com"],"url":"https:\/\/itbusinesstoday.com\/ja\/author\/newsdesk\/"}]}},"authors":[{"term_id":205,"user_id":4,"is_guest":0,"slug":"newsdesk","display_name":"NewsDesk","avatar_url":{"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","url2x":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png"},"author_category":"","first_name":"NewsDesk","last_name":"","user_url":"https:\/\/itbusinesstoday.com","job_title":"","description":""}],"_links":{"self":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/37554","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/comments?post=37554"}],"version-history":[{"count":1,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/37554\/revisions"}],"predecessor-version":[{"id":37555,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/37554\/revisions\/37555"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media\/37592"}],"wp:attachment":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media?parent=37554"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/categories?post=37554"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/tags?post=37554"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/ppma_author?post=37554"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}